Amgen Inc. has released pricing information for...

...its newly approved osteoporosis injectable, Evenity. The treatment will cost $1,825 per month, up to 74% lower than existing therapies, according to Amgen’s analysis. Evenity will go up against Radius Health’s Tymlos, Eli Lilly's Forteo and Amgen's own Prolia, an older therapy that only holds preferred status for 5% of covered lives. Of the three drugs, Tymlos is the current market leader, holding preferred status for 23% of covered lives, which grows to 44% including prior authorization and/or step therapy.

SOURCE: MMIT Analytics, as of 4/17/19